Comparative efficacy of multikinase inhibitors in the treatment of squamous cell carcinoma in cats
Open Access
- 25 February 2026
- journal article
- Published by Peoples' Friendship University of Russia in RUDN Journal of Agronomy and Animal Industries
- Vol. 20 (4) , 658-669
Abstract
The use of tyrosine kinase inhibitors (TKIs) in the treatment of oncological patients is reviewed. Feline oral squamous cell carcinoma (FOSCC) is locally aggressive disease affecting the epithelium. It can rapidly metastasise to soft tissues and bone structures, causing severe pain and loss of function in affected organs. Recently, tyrosine kinase inhibitors, for example, drugs with active substance toceranib were used for the implementation of anti-cancer treatment in veterinary medicine. Currently, toceranib phosphate (commercial drug Palladia) is unavailable in Russia, making the use of drugs with similar mechanisms of action highly relevant. The aim of the study was to compare the efficacy of toceranib and sorafenib tyrosine kinase inhibitors in the treatment of FOSCC. The object of the study was 30 cats of different breeds with confirmed FOSCC. The diagnosis was established based on physical examination and results of cytological and histological studies. Computer tomography(CT) was performed to determine tumour localisation and lymph node involvement. The animals were divided into three groups: group 1 received sorafenib, group 2 received toceranib, and group 3 (control) received no anticancer therapy. Some cats in groups 1 and 2 underwent surgical treatment as indicated. The study assessed overall survival time and time to progression. According to the results of the study, the average life expectancy of animals in group 1 was 112.4±29.1 days, in 2—98.1±18.8 days, in 3—24.2±3.6 days. The average duration of the non-recurrence period in the group 1 is 85,3±17.1 days, in the group 2 —86.8±13.0days. Therefore, In the treatment of head-region SCC in cats, sorafenib demonstrates efficacy comparable to that of toceranib and may serve as a substitute on the Russian market. Moreover, modelling anticancer therapy in small companion animals may inform the development of treatment protocols for human oncological patients.Keywords
This publication has 14 references indexed in Scilit:
- The MEK inhibitor trametinib is effective in inhibiting the growth of canine oral squamous cell carcinomaScientific Reports, 2025
- Analysis of VEGFR-2 and PDGFR-² expression in canine splenic hemangiosarcoma to identify drug repositioning candidatesBrazilian Journal of Veterinary Medicine, 2024
- Superficial kilovoltage x-ray radiotherapy for the treatment of cutaneous mast cell tumors on the head in three dogs and one cat: a limited retrospective case seriesJournal of the American Veterinary Medical Association, 2023
- Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous TumorsFrontiers in Veterinary Science, 2022
- The role of toceranib phosphate in dogs with non‐mast cell neoplasia: A systematic reviewVeterinary and Comparative Oncology, 2022
- Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinomaJournal of Veterinary Medical Science, 2022
- Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogsJournal of Veterinary Internal Medicine, 2020
- Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastineVeterinary and Comparative Oncology, 2019
- Tolerability of oral sorafenib in pet dogs with a diagnosis of cancerVeterinary Medicine: Research and Reports, 2017
- Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinomaJournal of Feline Medicine and Surgery, 2016